Company News
Mirum Pharmaceuticals Stock Surges 12% on Trial Results
Mirum Pharmaceuticals shares jumped about 12% after its VISTAS Phase 2b trial of volixibat met primary endpoint in PSC patients.
The study showed a 2.72‑point baseline itch reduction and 1.64‑point pl
